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Sex Prevalence of Major Congenital Anomalies in the United
Kingdom: A National Population-Based Study and International
Comparison Meta-analysis
Rachel Sokal*, Laila J. Tata, and Kate M. Fleming
Background: The aim of this study was to assess sex differences in major
congenital anomaly (CA) diagnoses within a national population sample; to
examine the influence of sociodemographic and maternal factors on these
risks; and to conduct a meta-analysis using estimates from other population-
based studies. Methods: We conducted a population-based study in a United
Kingdom research database of prospectively collected primary care data (The
Health Improvement Network) including children born 1990 to 2009
(n5 794,169) and identified major CA diagnoses using EUROCAT (European
Surveillance of Congenital Anomalies) classification. Prevalence ratios (PR)
were used to estimate the risk of CA in males compared with females for any
CA, system-specific subgroups and specific CA diagnoses. In a subpopulation
of children whose medical records were linked to their mothers’, we assessed
the effect of adjusting for sociodemographic and maternal factors on sex odds
ratios. PRs were pooled with measures from previously published studies.
Results: The prevalence of any CA was 307/10,000 in males (95% CI, 302–
313) and 243/10,000 in females (95% CI, 238–248). Overall the risk of any
CA was 26% greater in males (PR (male: female) 1.26, 95% CI, 1.23–1.30)
however there was considerable variation across specific diagnoses. The
magnitude and direction of risk did not change for any specific CA upon
adjustment for sociodemographic and maternal factors. Our PRs were highly
consistent with those from previous studies. Conclusion: The overall risk of
CA is greater in males than females, although this masked substantial
variation by specific diagnoses. Sociodemographic and maternal factors do
not appear to affect these risks.
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Introduction
Sex differences in several specific congenital anomalies
(CA) have been documented as far back as the 1940s
(Fogh-Andersen, 1942). Studies have reported conditions
such as cleft lip and polydactyly to be more common in
males (Hay, 1971), whereas neural tube defects (Deak
et al., 2008) and cleft palate (Natsume et al., 2000) are
reportedly more common in females. However, these initial
observations were limited to one or a few specific diagno-
ses within small selected patient groups and the contribu-
tions of other risk factors with known associations with
CAs and possible links to sex differentiation such as
maternal age (Chahnazarian, 1988), smoking (Fukuda
et al., 2002), diabetes (Rjasanowski et al., 1998), and epi-
lepsy (James, 2000) were not examined.
Using large population-based resources such as birth
or CA registries offers the potential to examine sex differ-
ences across the whole spectrum of CAs (Lary and Pau-
lozzi, 2001). However, CA registries tend to be limited to
specific geographical areas and vary in their methods of
case ascertainment (Boyd et al., 2005) so may not all be
representative of general populations. Additionally, they do
not routinely collect comprehensive sociodemographic and
maternal information nor details of children without CAs
(Boyd et al., 2011) and, therefore, are unable to assess the
potential impact of these factors on sex differences. Conse-
quently, studies using these data may not be able to fully
isolate sex-specific differences in CAs.
We aimed to estimate sex ratios in specific major CA
diagnoses using a large source of routine healthcare data
representative of the United Kingdom (U.K.) population
and to examine the effects of sociodemographic and
maternal factors on these ratios. We compared the direc-
tion and magnitude of our sex ratio estimates with those
of published population-based studies obtained from a
systematic search of the published literature and calcu-
lated pooled effect measures.
Materials and Methods
STUDY POPULATION
The Health Improvement Network (THIN) is a computer-
ized database of anonymized patient records from primary
care in the United Kingdom. THIN data covers approxi-
mately 6% of the U.K. population (Cegedim Srategic Data,
2013). It is broadly representative of the U.K. population
although is slightly more affluent (22.5% of THIN popula-
tion live in most affluent areas compared with 20.0% of
the national population according to national census-
derived measures of household socioeconomic position)
and includes a greater proportion of the population in the
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south of England (8.9%), Scotland (8.5%), and Wales
(7.4%) compared with London (4.6%) and the Midlands
(4.8%) (Blak et al., 2011). In September 2010, when the
data used in this study were downloaded, 495 general
practices were contributing data from over 9.5 million
patients across the U.K. population. Our study population
was all children in THIN born between 1990 and 2009
inclusive who were registered with their general practice
before their first birthday.
CASE DEFINITION AND CLASSIFICATION OF CONGENITAL ANOMALIES
THIN collates information of patients’ diagnoses and medi-
cal interventions at the time of consultation with primary
care staff or from electronic and letter communication from
secondary care institutions for diagnoses and tests that
require complex assessment. All such records are entered
into patients’ electronic health records using the Read Clini-
cal Classification system (Read codes), which is the stand-
ard coding system across all general practices in the United
Kingdom. We identified all major CAs in children’s general
practice records using Read codes mapped to the European
Surveillance of Congenital Anomalies (EUROCAT) classifica-
tion system (EUROCAT, 2008) excluding CAs defined by
EUROCAT as minor (EUROCAT, 2005). Congenital anomalies
were categorized into 15 system-specific subgroups accord-
ing to EUROCAT groupings (EUROCAT, 2008). These sub-
groups are broadly anatomical with an ‘Other’ group, which
includes disorders not included elsewhere such as skin dis-
orders and situs inversus. We have published a full descrip-
tion of the case definitions and classification methodology
elsewhere. In this work, we show across all system-specific
groups (and specific CA diagnoses for the most prevalent
system-specific subgroups) that prevalence estimates are
comparable between THIN and the U.K. registries of the
EUROCAT network and so demonstrate THIN to be a valid
and complete source of data to investigate CAs in live-born
children (Sokal et al., 2013).
STATISTICAL ANALYSIS
Birth prevalence of CAs overall was calculated as the num-
ber of live-born children with one or more CA diagnoses
per 10,000 live births for males and females separately
and 95% confidence intervals (CIs) for these prevalence
estimates were calculated based on a binominal distribu-
tion. We then calculated male and female prevalence esti-
mates for each system-specific subgroup (one or more CA
diagnosis within the same subgroup / 10,000 live births)
and for specific CA diagnoses. We also calculated the prev-
alence of having a single, isolated CA diagnosis and the
prevalence of multiple CA diagnoses (children with two or
more CA diagnoses / 10,000 live births). Sex-specific chro-
mosomal anomalies, e.g., Turner syndrome, and diagnoses
of indeterminate sex, were excluded from analysis of spe-
cific CAs diagnoses but were included in the overall and
system-specific subgroup prevalence measures. Prevalence
ratios (PR) with 95% CIs were used to compare CA preva-
lence in males with females (M:F) at all levels described
above.
To assess the potential effects of sociodemographic and
maternal factors on these ratios, we used a subpopulation
of children whose primary care medical records had been
linked to those of their mothers’ and where each mother
had been registered with the practice before the estimated
date of conception. Using logistic regression with a cluster
term to adjust for multiple births to the same woman, we
calculated the unadjusted odds ratios (OR) of any CA,
system-specific CA subgroups and specific CA diagnoses in
males compared with females and their 95% CIs. We then
calculated adjusted ORs to account for the combined effect
of factors available within our data that had established
associations with CA and hypothesized links to sex differen-
ces, namely: socioeconomic status (SES, as measured by the
Townsend Index of social and economic deprivation (Town-
send et al., 1988), according to the child’s home postcode),
geographical area, year of birth, maternal age at delivery,
maternal smoking status (at birth or in the year before
pregnancy; classified as current smoker, ex-smoker, or never
smoker); body mass index (BMI) before pregnancy (most
recent BMI measure in the year before pregnancy), whether
or not the mother had a diagnosis of diabetes before the
pregnancy (defined as any code of type I or type II diabetes
or insulin prescription), and whether or not the mother
was prescribed any anti-epileptic drug in the 3 months
before or in the first trimester of pregnancy. We compared
the unadjusted and adjusted measures for any CA, each
system-specific subgroup and specific CAs to identify
changes of 5% or greater in the ORs of the two models.
All analyses were conducted using Stata v11 (Stata-
Corp, Texas, U.S.A.).
SYSTEMATIC REVIEW AND POOLED RISK MEASURES
We systematically searched the literature using MEDLINE
and EMBASE databases and references of selected papers
to identify population-based studies that considered sex-
differences in the prevalence of one or more specific CA
using the following search terms: “sex” OR “sex differ-
entiation” OR “sex difference*” AND “congenital anomal*”
OR “congenital abnormal*” OR “birth defect*” OR
“congenital malformation*”. We included original research
published from 1960 until February 2013. We screened
the titles, abstracts and full-text of papers to identify stud-
ies for inclusion in our review. We included papers which
had assessed the sex prevalence of one or more CA at pop-
ulation level and excluded papers which had selected
cases from patient populations. We compared the PRs and
95% CI for specific CAs across studies where they had
been consistently defined in at least three studies includ-
ing our own and calculated pooled measures of effect
using published numerator and denominator data within
the identified studies to calculate weighted averages.
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In all analyses, we have reported 95% CIs as an indica-
tion of the precision of the estimate, however due to the
number of outcomes in our study we have not interpreted
them as an indication of statistical significance per se.
Results
POPULATION CHARACTERISTICS
In total, 794,169 children were included in the study pop-
ulation of whom 51.4% were male (Table 1). Of all
TABLE 1. Distribution of Sociodemographic Factors for the Total Population (N5 794,169) and of Maternal Factors for the Subpopulationa (N5571,807) for
Male and Female Children Separately
Male Female Male Female
n (%) n (%) n (%) n (%)
Total population 408,184 (51.4) 385,985 (48.6) Subpopulation* 293,815 (51.4) 277,992 (48.6)
Any congenital anomaly 12,537 (3.1) 9,394 (2.4) Any congenital anomaly 9,445 (3.2) 7,056 (2.5)
Sociodemographic factors Maternal factors
Geographical area Age
East Midlands 17,653 (4.3) 16,518 (4.3) <20 17,808 (6.1) 16,775 (6.0)
East of England 33,182 (8.1) 31,145 (8.1) 20–24 52,316 (17.8) 49,349 (17.8)
London 43,453 (10.6) 42,087 (10.9) 25–29 86,503 (29.4) 81,729 (29.4)
North East 12,833 (3.1) 12,278 (3.2) 30–34 87,862 (29.9) 83,077 (29.9)
North West 40,832 (10.0) 38,537 (10.0) 35–39 41,549 (14.1) 39,643 (14.3)
Northern Ireland 15,929 (3.9) 15,292 (4.0) >540 7,777 (2.6) 7,419 (2.7)
Scotland 42,643 (10.4) 40,257 (10.4)
South Central 48,841 (12.0) 45,433 (11.8) Body mass index
South East Coast 38,005 (9.3) 36,055 (9.3) Normal 101,739 (34.6) 96,465 (34.7)
South West 39,576 (9.7) 37,550 (9.7) Underweight 19,790 (6.7) 18,600 (6.7)
Wales 21,663 (5.3) 20,514 (5.3) Overweight 36,765 (12.5) 34,953 (12.6)
West Midlands 36,752 (9.0) 34,500 (8.9) Obese 17,512 (6.0) 16,698 (6.0)
Yorkshire & Humber 16,822 (4.1) 15,819 (4.1) Morbidly obese 2,149 (0.7) 2,031 (0.7)
Missing data 115,860 (39.4) 109,245 (39.3)
Year of birth
1990–1994 85,614 (21.0) 79,842 (20.7) Smoking status
1995–1999 99,611 (24.4) 94,533 (24.5) Non-smoker 66,524 (22.6) 62,924 (22.6)
2000–2004 104,623 (25.6) 99,476 (25.8) Current smoker 36,942 (12.6) 35,167 (12.7)
2005–2009 118,336 (29.0) 112,134 (29.1) Ex-smoker 88,804 (30.2) 84,116 (30.3)
Missing data 101,545 (34.6) 95,785 (34.5)
SES (Townsend)
1 - most deprived 92,045 (22.5) 86,942 (22.5) Diabetes
2 76,761 (18.8) 72,300 (18.7) Yes 1,693 (0.6) 1,498 (0.5)
3 78,583 (19.3) 74,373 (19.3)
4 74,818 (18.3) 70,636 (18.3) Epilepsy drugs
5 - least deprived 56,556 (13.9) 53,702 (13.9) Yes 1,348 (0.5) 1,288 (0.5)
Missing 29,421 (7.2) 28,032 (7.3)
aSubpopulation included only children whose medical records were linked to their mother’s records and thus had available maternal factors for
analysis (this was 72% of the total population). Distribution of sociodemographic factors were identical to the total population.
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children 21,931 had at least one diagnosis of a CA, a prev-
alence of 276 per 10,000 live births (95% CI, 273–280).
There were 571,807 children in the subpopulation of chil-
dren whose medical records were linked to those of their
mother, representing 72% of our total population. This
subpopulation was also 51.4% male. The distribution of
children by year of birth, geographical area, SES, and
maternal risk factors were similar in males and females
(Table 1).
SEX PREVALENCE
Numbers and prevalence of any CA and each system-
specific subgroup for males and females in the total popu-
lation are shown in Table 2 alongside the male to female
(M:F) PRs. The prevalence of any CA was 307 per 10,000
in males (95% CI, 302–313) and 243 per 10,000 in
females (95% CI, 238–248) with the overall risk of any CA
being 26% greater in males than in females (PR
[M:F]1.26; 95% CI, 1.23–1.30). We found the risk of multi-
ple CAs in males compared with females to be even
greater than that of a single diagnosis (one diagnosis PR
[M:F] 1.19, 95% CI, 1.16–1.23; multiple diagnoses 1.53,
95% CI, 1.43–1.63).
Prevalence ratios varied considerably across the 15
system-specific subgroups. The risk of CA was greater in
males for five subgroups: genital (PR [M:F] 16.6; 95% CI,
14.2–19.4), urinary (1.53; 95% CI, 1.39–1.67), musculo-
skeletal (1.36; 95% CI, 1.20–1.54), and digestive (1.29;
95% CI, 1.12–1.49) disorders, and orofacial clefts (1.20;
95% CI, 1.07–1.34). The only subgroup which showed a
lower risk in males was limb defects (PR [M:F] 0.71, 95%
0.67–0.75). There was little difference between sexes in
the prevalence of CAs for the remaining system-specific
subgroups.
The PR at a system-specific subgroup level masked
considerable variation in prevalence ratios of specific diag-
noses (Table 3). Nervous system anomalies showed little
variation by sex except for hydrocephaly where the risk
was 31% higher in males (PR [M:F] 1.31, 95% CI, 1.09–
1.59). There were no apparent differences in the sex prev-
alence of specific diagnoses of eye or ear, face, and neck
defects. For congenital heart anomalies, although we found
TABLE 2. Number and Prevalence of System-Specific Congenital Anomalies by Sex and Male to Female (M:F) Prevalence Ratios (N5794,169)
Male Female Prevalence ratio
N
Prevalence
(per 10,000 births) 95% CI N
Prevalence
(per 10,000 births) 95% CI M:F 95% CI
Any congenital anomaly 12,537 307 (302, 313) 9,394 243 (238, 248) 1.26 (1.23, 1.30)
One isolated diagnosis 9,292 228 (223, 232) 7,378 191 (187, 196) 1.19 (1.16, 1.23)
Multiple diagnoses 2,192 53.7 (51.5, 56.0) 1,359 35.2 (33.4, 37.1) 1.53 (1.43, 1.63)
Any system specific
Nervous System 657 16.1 (14.9, 17.4) 584 15.1 (13.9, 16.4) 1.06 (0.95, 1.19)
Eye 451 11.0 (10.1, 12.1) 376 9.7 (8.8, 10.8) 1.13 (0.99, 1.30)
Ear, face, and neck 105 2.6 (2.1, 3.1) 98 2.5 (2.1, 3.1) 1.01 (0.77, 1.33)
Heart 3,100 75.9 (73.3, 78.7) 3,060 79.3 (76.5, 82.1) 0.96 (0.91, 1.01)
Respiratory 286 7.0 (6.2, 7.9) 235 6.1 (5.3, 6.9) 1.15 (0.97, 1.37)
Orofacial clefts 647 15.9 (14.7, 17.1) 511 13.2 (12.1, 14.4) 1.20 (1.07, 1.34)
Digestive 453 11.1 (10.1, 12.2) 332 8.6 (7.7, 9.6) 1.29 (1.12, 1.49)
Abdominal wall 110 2.7 (2.2, 3.2) 108 2.8 (2.3, 3.4) 0.96 (0.74, 1.26)
Urinary 1,211 29.7 (28.0, 31.4) 750 19.4 (18.1, 20.9) 1.53 (1.39, 1.67)
Genital 2,879 70.5 (68.0, 73.2) 164 4.2 (3.6, 5.0) 16.6 (14.2, 19.4)
Limb 1,804 44.2 (42.2, 46.3) 2,408 62.4 (59.9, 64.9) 0.71 (0.67, 0.75)
Musculoskeletal 599 14.7 (13.5, 15.9) 416 10.8 (9.8, 11.9) 1.36 (1.20, 1.54)
Other malformations 395 9.7 (8.7, 10.7) 384 9.9 (9.0, 11.0) 0.97 (0.85, 1.12)
Chromosomal 764 18.7 (17.4, 20.1) 656 17.0 (15.7, 18.3) 1.10 (0.99, 1.22)
Genetic 354 8.7 (7.8, 9.6) 293 7.6 (6.7, 8.5) 1.14 (0.98, 1.33)
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TABLE 3. Number and Prevalence of Specific Congenital Anomalies by Sex and Male to Female (M:F) Prevalence Ratiosa
Male Female Prevalence ratio
N
Prevalence (per
10,000 births) 95% CI N
Prevalence (per
10,000 births) 95% CI M:F 95% CI
Nervous system
Hydrocephaly 253 6.2 (5.5, 7.0) 182 4.7 (4.1, 5.5) 1.31 (1.09, 1.59)
Microcephaly 191 4.7 (4.0, 5.4) 181 4.7 (4.0, 5.4) 1.00 (0.81, 1.22)
Neural tube defects 61 1.5 (1.1, 1.9) 75 1.9 (1.5, 2.4) 0.77 (0.55, 1.08)
Spina bifida 50 1.2 (0.9, 1.6) 57 1.5 (1.1, 1.9) 0.83 (0.57, 1.21)
Encephalocele 11 0.3 (0.1, 0.5) 16 0.4 (0.2, 0.7) 0.65 (0.30, 1.40)
Eye
Congenital cataract 82 2.0 (1.6, 2.5) 79 2.0 (1.6, 2.6) 0.98 (0.72, 1.34)
Ano’ / microphthalmos 67 1.6 (1.3, 2.1) 56 1.5 (1.1, 1.9) 1.13 (0.79, 1.61)
Anophthalmos 10 0.2 (0.1, 0.5) 5 0.1 (0.0, 0.3) 1.89 (0.65, 5.53)
Congenital glaucoma 33 0.8 (0.6, 1.1) 28 0.7 (0.5, 1.0) 1.11 (0.67, 1.84)
Ear, face, and neck
Anotia 6 0.1 (0.1, 0.3) <5 – – 5.67 (0.68, 47.1)
Heart
Ventricular septal defect 1,411 34.6 (32.8, 36.4) 1,379 35.7 (33.9, 37.7) 0.97 (0.90, 1.04)
Severe CHD 617 15.1 (13.9, 16.4) 418 10.8 (9.8, 11.9) 1.40 (1.23, 1.58)
Coarctation of aorta 159 3.9 (3.3, 4.6) 101 2.6 (2.1, 3.2) 1.49 (1.16, 1.91)
Tetralogy of Fallot 156 3.8 (3.2, 4.5) 131 3.4 (2.8, 4.0) 1.13 (0.89, 1.42)
Transposition of great vessels 102 2.5 (2.0, 3.0) 45 1.2 (0.9, 1.6) 2.14 (1.51, 3.04)
Atrioventricular septal defect 51 1.2 (0.9, 1.6) 56 1.5 (1.1, 1.9) 0.86 (0.59, 1.26)
Hypoplastic left heart 35 0.9 (0.6, 1.2) 12 0.3 (0.2, 0.5) 2.76 (1.43, 5.31)
Pulmonary valve atresia 29 0.7 (0.5, 1.0) 18 0.5 (0.3, 0.7) 1.52 (0.85, 2.74)
Total anom pulm venous return 23 0.6 (0.4, 0.8) 17 0.4 (0.3, 0.7) 1.28 (0.68, 2.39)
Ebstein anomaly 8 0.2 (0.1, 0.4) 15 0.4 (0.2, 0.6) 0.50 (0.21, 1.19)
Common arterial truncus 5 0.1 (0.0, 0.3) <5 – – 4.73 (0.55, 40.5)
Atrial septal defect 460 11.3 (10.3, 12.3) 596 15.4 (14.2, 16.7) 0.73 (0.65, 0.82)
Aortic valve atresia/stenosis 74 1.8 (1.4, 2.3) 33 0.9 (0.6, 1.2) 2.12 (1.41, 3.20)
Pulmonary valve stenosis 53 1.3 (1.0, 1.7) 51 1.3 (1.0, 1.7) 0.98 (0.67, 1.44)
Hypoplastic right heart 7 0.2 (0.1, 0.4) <5 – – 1.65 (0.48, 5.65)
Respiratory
Choanal atresia 29 0.7 (0.5, 1.0) 30 0.8 (0.5, 1.1) 0.91 (0.55, 1.52)
Cystic adenomatous malf lung 5 0.1 (0.0, 0.3) <5 – – 1.18 (0.32, 4.40)
Cleft lip or palate
Cleft lip with/out palate 384 9.4 (8.5, 10.4) 223 5.8 (5.0, 6.6) 1.63 (1.38, 1.92)
Cleft palate 263 6.4 (5.7, 7.3) 288 7.5 (6.6, 8.4) 0.86 (0.73, 1.02)
Digestive system
Hirschsprung’s disease 112 2.7 (2.3, 3.3) 45 1.2 (0.9, 1.6) 2.35 (1.67, 3.33)
Anorectal 105 2.6 (2.1, 3.1) 68 1.8 (1.4, 2.2) 1.46 (1.08, 1.98)
Esophageal atresia 62 1.5 (1.2, 1.9) 42 1.1 (0.8, 1.5) 1.40 (0.94, 2.07)
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little overall difference in risk between sexes at system
level (PR [M:F] 0.96; 95% CI, 0.91–1.01), disorders catego-
rized as “severe” according to EUROCAT classification
appeared more prevalent in males than females (PR [M:F]
1.40; 95% CI, 1.23–1.58) driven by the higher risk in
males of coarctation of aorta, transposition of great vessels
TABLE 3. Continued
Male Female Prevalence ratio
N
Prevalence (per
10,000 births) 95% CI N
Prevalence (per
10,000 births) 95% CI M:F 95% CI
Oth. parts sm intestine 27 0.7 (0.4, 1.0) 32 0.8 (0.6, 1.2) 0.80 (0.48, 1.33)
Diaphragmatic hernia 15 0.4 (0.2, 0.6) 8 0.2 (0.1, 0.4) 1.77 (0.75, 4.18)
Duodenal 13 0.3 (0.2, 0.5) 26 0.7 (0.4, 1.0) 0.47 (0.24, 0.92)
Abdominal wall defects
Gastroschisis 74 1.8 (1.4, 2.3) 85 2.2 (1.8, 2.7) 0.82 (0.60, 1.12)
Omphalocele 33 0.8 (0.6, 1.1) 23 0.6 (0.4, 0.9) 1.36 (0.80, 2.31)
Urinary system
Hydronephrosis 154 3.8 (3.2, 4.4) 52 1.3 (1.0, 1.8) 2.80 (2.05, 3.83)
Renal dysplasia 78 1.9 (1.5, 2.4) 35 0.9 (0.6, 1.3) 2.11 (1.41, 3.14)
Bladder exstrophy/epispadias 77 1.9 (1.5, 2.4) 11 0.3 (0.1, 0.5) 6.62 (3.52, 12.5)
Posterior urethral valve 49 1.2 (0.9, 1.6) <5 – – 23.2 (5.63, 95.3)
Genital
Hypospadias 2,581 63.2 (60.8, 65.7) <5 – – 814 (262, 2520)
Limb
Club foot 632 15.5 (14.3, 16.7) 468 12.1 (11.1, 13.3) 1.28 (1.13, 1.44)
Hip dislocation/dysplasia 366 9.0 (8.1, 9.9) 1,318 34.1 (32.3, 36.0) 0.26 (0.23, 0.29)
Polydactyly 312 7.6 (6.8, 8.5) 211 5.5 (4.8, 6.3) 1.40 (1.17, 1.67)
Syndactyly 223 5.5 (4.8, 6.2) 136 3.5 (3.0, 4.2) 1.55 (1.25, 1.92)
Limb reduction 133 3.3 (2.7, 3.9) 129 3.3 (2.8, 4.0) 0.97 (0.77, 1.24)
Lower limb reduction 70 1.7 (1.3, 2.2) 89 2.3 (1.9, 2.8) 0.74 (0.54, 1.02)
Upper limb reduction 49 1.2 (0.9, 1.6) 29 0.8 (0.5, 1.1) 1.60 (1.01, 2.53)
Limb reduction other 18 0.4 (0.3, 0.7) 13 0.3 (0.2, 0.6) 1.31 (0.64, 2.67)
Arthrogryposis multi congenital 10 0.2 (0.1, 0.5) 9 0.2 (0.1, 0.4) 1.05 (0.43, 2.59)
Musculoskeletal
Craniosynostosis 137 3.4 (2.8, 4.0) 35 0.9 (0.6, 1.3) 3.70 (2.55, 5.37)
Achondroplasia 37 0.9 (0.6, 1.2) 23 0.6 (0.4, 0.9) 1.52 (0.90, 2.56)
Other
Disorders of skin 133 3.3 (2.7, 3.9) 89 2.3 (1.9, 2.8) 1.41 (1.08, 1.85)
Situs inversus 16 0.4 (0.2, 0.6) 14 0.4 (0.2, 0.6) 1.08 (0.53, 2.21)
Asplenia 9 0.2 (0.1, 0.4) 7 0.2 (0.1, 0.4) 1.22 (0.45, 3.26)
Chromosomal
Down syndrome 407 10.0 (9.0, 11.0) 371 9.6 (8.7, 10.6) 1.04 (0.90, 1.19)
Wolf-Hirschhorn synd 9 0.2 (0.1, 0.4) 6 0.2 (0.1, 0.3) 1.42 (0.50, 3.99)
Edward syndrome <5 – – 10 0.3 (0.1, 0.5) 0.38 (0.12, 1.21)
Patau syndrome <5 – – 5 0.1 (0.0, 0.3) 0.76 (0.20, 2.82)
aOnly CAs with at least ten cases are included in the table. Where the number of cases in a single sex is less than five, the PR has been dis-
played but the number and sex prevalence censored.
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and hypoplastic left heart. Aortic valve disorders were also
more prevalent in males (PR [M:F] 2.12; 95% CI, 1.41–
3.20); conversely atrial septal defects were more common
in females (PR [M:F] 0.73; 95 CI, 0.65–0.82).
There were no apparent differences in the sex preva-
lence of specific respiratory anomalies. For cleft lip (with
or without palate), we detected a risk over 60% higher in
males compared with females (PR [M:F] 1.63; 95% CI,
1.38–1.92) but found a lower risk in males for cleft palate
alone although CIs included the null value (PR [M:F] 0.86;
95% CI, 0.73–1.02). The PRs for digestive system disor-
ders varied substantially across specific diagnoses. The
risk of Hirschsprung’s disease (PR [M:F] 2.35; 95% CI,
1.67–3.33) was greater in males compared with females
whereas duodenal diagnoses were lower (PR [M:F] 0.47;
95% CI, 0.24–0.92). For abdominal disorders, the risk of
gastroschisis was greater in females (PR [M:F] 0.82; 95%
CI, 0.60–1.12) and the risk of omphalocele was greater in
males (PR [M:F] 0.36; 95% CI, 0.80–2.31); however, the
CIs for both these estimates were wide and included the
null value. The risk of each specific urinary disorder was
greater in males than in females.
Hypospadias accounted for 90% of genital disorders in
males compared with just 2% in females. Excluding hypo-
spadias from the overall risk measure for genital disorders
reduced the PR (M:F) from 16.6 (95% CI, 14.2–19.4) to
1.83 (95% CI, 1.51–2.22). The overall lower risk of limb
defects in males compared with females was driven by a
substantial female preponderance of hip dislocation/dys-
plasia the risk of which was 74% lower in males (PR
[M:F] 0.26; 95% CI, 0.23–0.29), whereas the risk of some
other specific diagnoses was higher in males (e.g., club
foot, polydactyly). For musculoskeletal disorders, the prev-
alence of craniosynostosis was nearly four times higher in
males (PR [M:F] 3.70; 95% CI, 2.55–5.37) but other mus-
culoskeletal diagnoses showed little variation by sex.
Within the “Other” system-specific subgroup, skin disor-
ders were more prevalent in males (PR [M:F] 1.41; 95%
CI, 1.08–1.85). Within chromosomal disorders, the preva-
lence of Down syndrome did not differ between sexes (PR
[M:F] 1.04; CI, 0.90–1.19).
ADJUSTMENT FOR SOCIODEMOGRAPHIC AND MATERNAL FACTORS
In the subpopulation of 571,807 children where we had
access to children’s medical records linked to those of their
mothers’, the birth prevalence of CA was 289 per 10,000
live births (95% CI, 284–293). The sex prevalence ratio of
CAs for this subpopulation did not differ from the overall
population (PR [M:F] 1.27; 95% CI, 1.23–1.31) compared
with 1.26 (95% CI, 1.23–1.30) in the whole population of
794,169 children. Unadjusted odds of CA in males com-
pared with females did not change by more than 2.5% upon
adjustment for sociodemographic and maternal risk factors
for any, each system-specific subgroup or specific CA (sup-
plementary tables available online).
SYSTEMATIC REVIEW AND POOLED RISK MEASURES
We identified 425 publications in our search and reviewed
the full text of six with five studies included in the final
review (see Fig. 1) with the characteristics of these stud-
ies are presented in Table 4. The frequent use of some
the search terms, e.g., “sex” and “congenital anomaly,” in
the general key words of papers rather than as its specific
focus resulted in a large number of papers returned in
the search that were not relevant to the review, this led
to the large volume of studies removed at the title stage.
Nonrelevant papers typically did not assess sex differences
in prevalence or had cases selected from patient popula-
tions. We chose the wide search term approach as we
found using more specific search terms was too restrictive
due to the variety of different terms used by authors. All
included studies identified cases of congenital anomalies
from either CA or birth registries: three studies used
regional CA registries (Tennant et al. (2011), North of
England, UK, 1998–2003; Shaw et al. (2003), Calfornia,
USA 1989–1997; Lary & Paulozzi (2001), Atlanta, USA,
1968–1995); Lisi et al. (2005) used CA registry data from
several international registries from 1968 to 1998 with
registries contributing data at different times depending
on the circumstances of each; and Rittler et al. (2004)
identified cases from birth registry data from nine South
American countries from 1982 to 1999. The size of the
denominator population (size of population covered by
registry) ranged from 646,174 (Tennant et al., 2011) to
2,537,001 (Shaw et al., 2003) and the total numerator
(number of cases of CAs) size ranged from 12,795 (Ten-
nant et al., 2011) to 55,422 (Shaw et al., 2003), although
these figures were not available for all studies (see
Table 4). Due to the potential of overlapping cases and
baseline populations in two of the publications with those
of our study and the absence of denominator data in one,
we excluded two studies from the pooled analysis (Lisi
et al., 2005; Tennant et al., 2011).
The PR (M:F) for any CA in our study was consistent
with those of others. Lary and Paulozzi (2001) calculated
a male to female prevalence ratio of 1.38 (95% CI, 1.35–
1.41) and Shaw et al. (2003) calculated 1.42 (95% CI,
1.39–1.44); we calculated a pooled PR (M:F) of 1.37
(95% CI, 1.36–1.39) for any major CA. In the only pub-
lished U.K.-based study, Tennant et al. (2011) reported a
M:F prevalence ratio of 1.15 (95% CI, 1.11–1.19) for the
North of England congenital anomaly register (NORCAS),
however, this study omitted sex-linked urinary and geni-
tal anomalies in addition to chromosomal anomaly diag-
noses from their analysis and when recalculated our
overall PR with these exclusions it was 1.02 (95% CI,
0.99–1.05).
There was good agreement across studies for the
majority of sex prevalence ratios of specific CAs with the
precision of these estimates increasing in the pooled esti-
mates. For example, the PR (M:F) for spina bifida PR
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ranged from 0.72–0.86 in individual studies with a pooled
PR of 0.73 (95% CI, 0.67–0.80) and the PR (M:F) for cleft
lip PR ranged from 1.27–1.81 in individual studies with a
pooled PR 1.32 (95% CI, 1.24–1.40).
For many CAs PRs were consistent across the studies
with each measure close to the null value. The pooled
estimates indicated potential differences in the sex prev-
alence of several of these anomalies, for example ven-
tricular septal defect PR (M:F) 0.92 (95% CI, 0.88–0.96),
whereas for others the risk remained equivocal between
the sexes, e.g., Down syndrome PR (M:F) 1.04 (95% CI,
0.98–1.11). Where there was greater variation in the
point estimates between studies, this tended to be due
to smaller numbers of cases in rarer conditions with
large CIs which overlapped between studies, for exam-
ple Ebstein anomaly and cystic adenomatous malforma-
tion of the lung. For many of these individual estimates,
we were not able to calculate pooled estimates as indi-
vidual PRs were not reported in at least three separate
studies.
Discussion
We found that the prevalence of congenital anomalies was
26% higher in males compared with females (PR [M:F]
1.26; 95% CI, 1.23–1.30); however, this masked variation
across system-specific subgroups and specific diagnoses.
Adjusting for some important sociodemographic and
maternal risk factors known to be associated with preva-
lence of congenital anomalies and potentially to sex differ-
entiation did not change the magnitude of the ORs for any
specific CA or at a system level. Our results were highly
consistent with those from previous studies (Lary and
Paulozzi, 2001; Shaw et al., 2003; Rittler et al., 2004; Lisi
et al., 2005; Tennant et al., 2011).
This is the first study of a national U.K.-based popula-
tion to examine sex differences in congenital anomalies.
The pooled measures we calculated increased the confi-
dence in the estimates compared with any single study.
Our study, alongside others, has shown a greater number
of CAs in which there is a male predominance rather than
a female one. For CAs that have a greater predominance in
FIGURE 1. PRISMA flow diagram of
the identification of studies
included in the literature review.
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TABLE 4. Comparison of Sex Prevalence (PR, Male:Female) Ratios for Congenital Anomalies in Population-Based Studies and Pooled Estimates a
Current study
Tennant et al.
2011
Lisi et al.
2005
Rittler et al.
2004 Shaw et al. 2003
Lary & Paulozzi
2001 Pooledb
PR 95% CI PR 95% CI PR* PR 95% CI PR 95% CI PR 95% CI PR 95% CI
Total baseline
population (N)
794,169 646,174 NK 1,432,220 2,537,001 853,456
Total children
with CA (n)
21,931 12,795 NK NK 55,422 28,965
Any CA 1.26 (1.23, 1.30) 1.15 (1.11, 1.19) 1.42 (1.39, 1.44) 1.38 (1.35, 1.41) 1.37 (1.36, 1.39)
Multiple (two or more)
diagnoses
1.52 (1.44, 1.61) 1.43 (1.23, 1.67) 0.69 (0.52, 0.91)
Nervous system
Hydrocephaly 1.31 (1.09, 1.59) 1.32 (0.97, 1.79) 1.23 1.34 (1.16, 1.54) 1.02 (0.92, 1.13) 1.27 (1.07, 1.51) 1.17 (1.09, 1.26)
Microcephaly 1.00 (0.81, 1.22) 0.73 (0.48, 1.10) 0.61 (0.46, 0.81) 0.59 (0.54, 0.64) 0.67 (0.56, 0.81) 0.63 (0.59, 0.68)
Spina bifida 0.83 (0.57, 1.21) 0.83 (0.69, 0.99) 0.86 0.72 (0.64, 0.81) 0.72 (0.61, 0.86) 0.77 (0.60, 0.99) 0.73 (0.67, 0.80)
Encephalocele 0.65 (0.30, 1.40) 0.75 (0.45, 1.25) 0.72 0.83 (0.64, 1.08)
Arhinen’/
holoprosencephaly
0.47 (0.09, 2.58) 0.6 (0.31, 1.18) 0.61
Eye
Congenital cataract 0.98 (0.72, 1.34) 0.95 (0.54, 1.67) 0.86 (0.70, 1.05)
Ano’/microphthalmos 1.13 (0.79, 1.61) 1.7 (0.57, 5.08) 0.61 (0.53, 0.71)
Anophthalmos 1.89 (0.65, 5.53) 1.08 0.73 (0.47, 1.15)
Ear, face, and neck
Anotia 5.67 (0.68, 47.1) 2.6 (0.83, 8.17) 1.58
Heart 0.96 (0.91, 1.01) 1.01 (0.92, 1.10) 1.07 (1.02, 1.12) 1.02 (0.99, 1.05)
Ventricular septal defect 0.97 (0.90, 1.04) 0.95 (0.87, 1.04) 0.87 (0.74, 1.02) 0.89 (0.84, 0.95) 0.92 (0.88, 0.96)
Coarctation of aorta 1.49 (1.16, 1.91) 1.68 (1.25, 2.27) 1.31 1.29 (1.13, 1.47)
Tetralogy of Fallot 1.13 (0.89, 1.42) 1.28 (0.96, 1.71) 1.2 1.08 (0.94, 1.25)
Transposition
of great vessels
2.14 (1.51, 3.04) 2.01 (1.49, 2.72) 1.91 1.61 (1.42, 1.81) 1.38 (1.14, 1.68) 1.58 (1.44, 1.75)
Atrioventricular
septal defect
0.86 (0.59, 1.26) 0.74 (0.50, 1.10) 0.67 (0.59, 0.77)
Hypoplastic left heart 2.76 (1.43, 5.31) 1.45 (0.99, 2.13) 1.60 1.23 (1.01, 1.48) 1.34 (1.02, 1.76) 1.32 (1.14, 1.54)
Ebstein anomaly 0.50 (0.21, 1.19) 1.08 (0.65, 1.80) 0.91 (0.67, 1.24)
Common arterial truncus 4.73 (0.55, 40.5) 1.82 (0.93, 3.56) 0.99 (0.75, 1.30)
Atrial septal defect 0.73 (0.65, 0.82) 0.61 (0.49, 0.75) 1.00 (0.95, 1.05) 0.68 (0.51, 0.91) 0.94 (0.90, 0.99)
Aortic valve
atresia/stenosis
2.12 (1.41, 3.20) 2.50 (1.78, 3.49) 1.22 (1.03, 1.46) 1.58 (1.15, 2.17) 1.39 (1.20, 1.60)
Respiratory
Choanal atresia 0.91 (0.55, 1.52) 0.71 (0.25, 2.05) 0.91 (0.73, 1.14)
Cystic adenomatous
malf lung
1.18 (0.32, 4.40) 0.77 (0.37, 1.60) 1.50 (0.87, 2.60)
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TABLE 4. Continued
Current study
Tennant et al.
2011
Lisi et al.
2005
Rittler et al.
2004 Shaw et al. 2003
Lary & Paulozzi
2001 Pooledb
PR 95% CI PR 95% CI PR* PR 95% CI PR 95% CI PR 95% CI PR 95% CI
Cleft lip and palate
Cleft lip with/out palate 1.63 (1.38, 1.92) 1.81 (1.47, 2.24) 1.68 1.29 (1.15, 1.44) 1.27 (1.17, 1.37) 1.32 (1.24, 1.40)
Cleft palate 0.86 (0.73, 1.02) 0.75 (0.58, 0.98) 0.73 0.57 (0.43, 0.75) 0.67 (0.60, 0.75) 0.71 (0.65, 0.77)
Digestive system
Hirschsprung’s disease 2.35 (1.67, 3.33) 2.9 (1.62, 5.20) 2.69 (2.11, 3.42) 2.79 (1.95, 3.99) 2.63 (2.21, 3.12)
Anorectal 1.46 (1.08, 1.98) 3.21 (1.90, 5.43) 1.78
Esophageal atresia 1.40 (0.94, 2.07) 1.37 (0.93, 2.04) 1.30
Oth. parts sm intestine 0.80 (0.48, 1.33) 1.70 (0.57, 5.08) 0.92
Diaphragmatic hernia 1.77 (0.75, 4.18) 1.51 (1.11, 2.05) 1.34 1.12 (0.87, 1.45) 1.48 (1.11, 1.96) 1.29 (1.07, 1.55)
Abdominal wall defects
Gastroschisis 0.82 (0.60, 1.12) 0.93 (0.71, 1.22) 0.97 0.90 (0.69, 1.17)
Omphalocele 1.36 (0.80, 2.31) 0.97 (0.61, 1.55) 1.22
Urinary system
Hydronephrosis 2.80 (2.05, 3.83) 3.18 (2.49, 4.05) 2.92 (2.33, 3.66) 2.11 (1.74, 2.56) 2.50 (2.19, 2.85)
Bladder
exstrophy/epispadias
6.62 (3.52, 12.5) 1.22 (0.45, 3.27) 0.48 (0.12, 1.91)
Limb
Club foot 1.28 (1.13, 1.44) 1.68 (1.51, 1.87) 0.91 (0.81, 1.04) 1.75 (1.46, 2.10) 1.35 (1.27, 1.44)
Hip dislocation/
dysplasia
0.26 (0.23, 0.29) 0.31 (0.27, 0.37) 0.33 (0.28, 0.39) 0.29 (0.27, 0.32)
Polydactyly 1.40 (1.17, 1.67) 2.05 (1.03, 4.06) 1.30 1.24 (1.14, 1.34) 1.20 (1.10, 1.31) 1.45 (1.28, 1.63) 1.27 (1.21, 1.34)
Syndactyly 1.55 (1.25, 1.92) 2.08 (0.72, 5.99) 1.92 (1.54, 2.38) 1.43 (1.30, 1.57) 1.75 (1.42, 2.17) 1.53 (1.42, 1.65)
Lower limb reduction 0.74 (0.54, 1.02) 1.20 (0.69, 2.11) 1.19 (0.95, 1.50)
Upper limb reduction 1.60 (1.01, 2.53) 1.07 (0.76, 1.52) 1.03 (0.89, 1.19)
Musculoskeletal
Craniosynostosis 3.70 (2.55, 5.37) 1.77 (0.94, 3.31) 2.04 (1.63, 2.54)
Chromosomal
Down syndrome 1.04 (0.90, 1.19) 1.05 1.00 (0.93, 1.09) 1.16 (1.01, 1.33) 1.04 (0.98, 1.11)
Edward syndrome 0.38 (0.12, 1.21) 0.7 (0.53, 0.91) 0.72 0.63 (0.49, 0.80)
Patau syndrome 0.76 (0.20, 2.82) 0.95 (0.63, 1.43) 0.99 0.30 (0.21, 0.45)
aCongenital anomalies included in table if sex prevalence ratio published in current and at least two other studies.
bPooled measures calculated where data available in current and at least two other studies excluding Tennant et al. and Lisi et al. due to the
potential of shared population in both and no denominator data in the study from Lisi et al.
Current study: general practice population; UK-wide; 1990–2009. Tennant et al.: CA registry; North of England, UK; 1998–2003.
Lisi et al.: CA registry; international (19 registries: Europe n513, Americas n53, other n53) ; 1968–1998. (*No denominator data included;
published sex ratios adjusted for the study’s referent birth sex ratio of 1.06 thus 95% confidence intervals not known).
Rittler et al.: birth cohort; South America (9 countries); 1982–1999.
Shaw et al.: CA registry; California, USA; 1989–1997.
Lary & Paulozzi: CA registry; Atlanta, USA; 1968–1999.
NK – not known.
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males, the sex-specific risks tend to be of larger magnitude
(PR [M:F] >1.40), whereas for conditions in which there is
a female dominance the risk differences between sexes
tend to be smaller (PR [M:F] between 0.80 and 1.00).
These smaller differences are, therefore, statistically more
difficult to detect, but the consistency of female predomi-
nance across studies and the pooled measures we calcu-
lated support the likelihood of existing differences in the
prevalence between the sexes. As these risk differences
are statistically small, they may not be immediately impor-
tant in clinical practice yet they may offer further clues to
the causative mechanisms underlying these CAs as, despite
the consistency of sex ratios across studies, there remains
little clear evidence from physiological, biological, or endo-
crinological research to explain these differences. These
differences may also contribute to potential explanations
for some sex differences in later adult disease outcomes
that may have been initially related to CAs.
Primary care data have been shown to be a valid and
complete source of data in which to investigate congenital
anomalies (Wurst et al., 2007a, 2007b; Charlton et al.,
2010, 2011; Sokal et al., 2013). Using a U.K.-wide sample
of primary care data avoids some of the biases in case
ascertainment and data collection that can affect studies
using registry data (Rankin et al., 2005), although as it is
not possible to verify individual diagnoses within these
data, it is possible that some misclassification or under-
ascertainment exists. All of the other population-based
studies we identified and included in this review have uti-
lized birth cohort or CA registry data. This means that,
although they often study large populations, they have
either been limited to specific registries and therefore geo-
graphic areas (Lary and Paulozzi, 2001; Shaw et al., 2003;
Rittler et al., 2004; Tennant et al., 2011) or conversely,
have combined several international sources (Lisi et al.,
2005). Although there are obvious limitations of analyses
within single sources, the combination of multiple regis-
tries also can be problematic as in addition to demo-
graphic and environmental differences between
populations, case ascertainment and diagnostic criteria
may also differ between sources (Loane et al., 2011). Con-
sequently, the methodological validity of pooling multiple
sources in such a way to provide overall measures of sex
differences may not be robust. Despite this possible limita-
tion, we in fact found estimates to be remarkably similar
across all the studies included in the review suggesting
that this potential heterogeneity does not appear to affect
sex differences in CAs. This may in turn give further clues
to causative mechanisms by indicating factors such as
demographic and healthcare differences between popula-
tions may not be important mediators in the sex differen-
ces seen in CA prevalence.
Although our study was not able to include CAs diag-
nosed in pregnancies ending in stillbirth, termination of
pregnancy or spontaneous abortion, using information on
pregnancies resulting in live births only is consistent with
the majority of the population-based studies we identified
(Lary and Paulozzi, 2001; Shaw et al., 2003; Rittler et al.,
2004; Lisi et al., 2005). Only Tennant and colleagues
(2011) were able to include such cases in their analysis,
and the inclusion of these CAs in their analysis did not
result in substantially different PRs to those of other stud-
ies. There is however some evidence to suggest that there
may be selective late-miscarriage of males with neural
tube defects (K€allen et al., 1994) and sex-differences in
survival of fetuses may exist for other CAs (Lubinsky,
1997), thus real differences in sex prevalence from con-
ception may not be detected in studies limited to live
births only. Notwithstanding this, it is not possible to
know the number of pregnancies that spontaneously abort
at an early stage of pregnancy due to congenital anomaly
rendering it impossible to ever ascertain a measure of
prevalence that is completely free from this bias.
This is the first U.K. study to control for the effect of
potentially confounding variables. Our analysis indicated
sociodemographic and maternal factors did not affect the
sex prevalence of any CA, akin to the results found in the
work by Shaw et al. (2003) from California, U.S., where
adjustment for parity, maternal age, education, and ethnic-
ity did not affect the sex prevalence of CAs. We acknowl-
edge that the recording of some of these maternal risk
factors in our data was not complete, for example, smok-
ing status preconception, however we have been able to
examine many more risk factors than previously seen in
the only other study examining maternal risk factors. As
the proportions of missing data were identical between
boys and girls in our population, it is unlikely that this
would have had any substantial impact on the findings.
Although we do not have reason to believe that the sex
ratio of those with missing data should differ from those
without, we included missing data as a separate category
in our adjusted models so the potential for residual con-
founding should be considered when comparing unad-
justed ORs with those adjusted for sociodemographic and
maternal factors. For specific level diagnoses, there is of
course the issue of lack of power, thus we cannot conclude
definitively that these maternal risk factors do not influ-
ence the sex prevalence ratio for specific CA diagnoses.
Furthermore, although we were able to control for several
important variables, we did not have data available to
directly measure the effect of some other factors such as
maternal stress, which may be associated with sex differ-
entiation of fetuses (Chason et al., 2012) nor did we
attempt to adjust for maternal factors where the evidence
of an association with CAs in offspring remains equivocal,
for example, selective serotonin reuptake inhibitors (Diav-
Citrin and Ornoy, 2012).
Despite the consistency of findings across studies of
CA sex prevalence ratios, there remains little evidence
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from physiological, biological, or endocrinological research
to explain differences. Studies have found a low male to
female sex ratio of spontaneously aborted fetuses with an
anomaly compared with those without suggesting a better
survival rate to birth of male fetuses with anomalies com-
pared with females which could contribute to a higher
risk in live born children (Hay, 1971; Kellokumpu-
Lehtinen and Pelliniemi, 1984; Khoury et al., 1989). How-
ever, this pattern appears to be reversed in neural tube
defects (NTD), where survival of male fetuses has been
found to be poor compared with females, resulting in the
higher risk of NTDs in females at birth (K€allen et al.,
1994). The interaction of sex hormones and system devel-
opment has been cited as possible causes of sex differen-
ces in some anomalies including cleft palate and lip
(Nagase et al., 2010). Other theories for sex differences
include that the earlier time of gestation at which male
reproductive organs develop and their susceptibility to
excess hormone levels may account for the increased level
of male urinary and reproductive defects (Lubinsky, 1997;
Lary and Paulozzi, 2001), although there is little empirical
evidence to support these theories.
Conclusions
This study confirms the greater risk for males to be born
with major CAs and additionally highlights substantial var-
iation in this risk by system-specific subgroup and specific
diagnosis. Sociodemographic and maternal factors that
have been shown to affect the prevalence of CAs had no
effect on the relationship between CAs and sex. The large
population and pooled analyses in this study afforded us
increased statistical confidence in many of these estimates
and the nationally representative data provides generaliz-
ability to the wider population of the United Kingdom and
thus may give further clues as to the causative mecha-
nisms of CAs and means of prevention.
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